Literature DB >> 8260072

Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions.

P W Pisters1, D B Pearlstone.   

Abstract

Cancer cachexia is a complex syndrome characterized primarily by diminished nutrient intake and progressive tissue depletion that is manifest clinically as anorexia and host weight loss. The gradual loss of host protein stores is central to this process. This review outlines the techniques that have been used to evaluate human amino acid metabolism, their application in patients with cancer cachexia, and possible therapeutic interventions designed to overcome alterations in host protein and amino acid metabolism associated with malignant cachexia. The techniques of nitrogen balance and 3-methylhistidine excretion provide indirect estimates of overall nitrogen metabolism and skeletal muscle myofibrillar protein breakdown. Measurement of circulating amino acid concentrations, particularly when combined with assessment of arterial-venous differences and regional amino acid balance allows for investigation of interorgan amino acid metabolism. One of the most significant advances in in vivo amino acid metabolic research has been the development of labeled amino acid tracer studies to evaluate whole body and regional amino acid kinetics. The use of stable and unstable amino acid isotopes in these techniques is reviewed in detail. Virtually all of these techniques have now been employed in the evaluation of human cancer cachexia. The results of studies evaluating amino acid concentrations, regional amino acid balance, and 3-methylhistidine excretion are summarized. The use of regional and whole body kinetic studies in cancer cachexia are reviewed extensively. Most investigators have observed increased rates of whole body protein turnover, synthesis, and catabolism in both weight-stable and weight-losing cancer patients. Some studies have suggested a relationship between the extent of disease and the degree of aberration in amino acid kinetic parameters. Investigators have attempted to reverse some of these alterations by provision of substrate (nutritional support) or administration of specific pharmacologic or anabolic agents such as hydrazine sulfate, insulin, growth hormone, and beta-2 agonists. The role of total parenteral nutrition (TPN) in cancer and its effects on protein and amino acid kinetics and tumor growth are addressed. The possible benefits of specific amino acid nutritional formulations with increased branched chain amino acids, arginine, and glutamine are reviewed. Although many of these approaches appear promising, significant impact on clinically definable parameters remains to be demonstrated. A better understanding of the underlying protein catabolic mechanisms of cancer cachexia will likely lead to more effective therapies to reverse the protein calorie malnutrition associated with cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260072     DOI: 10.3109/10408369309084669

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  19 in total

1.  Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.

Authors:  M A McNurlan; P J Garlick; R T Steigbigel; K A DeCristofaro; R A Frost; C H Lang; R W Johnson; A M Santasier; C J Cabahug; J Fuhrer; M C Gelato
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker.

Authors:  Yutaka Ihata; Etsuko Miyagi; Reiko Numazaki; Takahiko Muramatsu; Akira Imaizumi; Hiroshi Yamamoto; Minoru Yamakado; Naoyuki Okamoto; Fumiki Hirahara
Journal:  Int J Clin Oncol       Date:  2013-05-23       Impact factor: 3.402

Review 3.  Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-05-19       Impact factor: 8.262

4.  A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy.

Authors:  M F Brennan; P W Pisters; M Posner; O Quesada; M Shike
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

Review 5.  Glutathione homeostasis in response to exercise training and nutritional supplements.

Authors:  C K Sen
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

6.  Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity.

Authors:  V Hack; O Stütz; R Kinscherf; M Schykowski; M Kellerer; E Holm; W Dröge
Journal:  J Mol Med (Berl)       Date:  1996-06       Impact factor: 4.599

7.  Reversal by growth hormone of homocysteine-induced epithelial-to-mesenchymal transition through membrane raft-redox signaling in podocytes.

Authors:  Cai-Xia Li; Min Xia; Wei-Qing Han; Xiao-Xue Li; Chun Zhang; Krishna M Boini; Xiao-Cheng Liu; Pin-Lan Li
Journal:  Cell Physiol Biochem       Date:  2011-06-17

Review 8.  Beta-hydroxy-beta-methylbutyrate (HMB) supplementation and the promotion of muscle growth and strength.

Authors:  G J Slater; D Jenkins
Journal:  Sports Med       Date:  2000-08       Impact factor: 11.136

9.  Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain.

Authors:  Jinyu Chen; Ho-Jeong Lee; Xuefeng Wu; Lei Huo; Sun-Jin Kim; Lei Xu; Yan Wang; Junqing He; Lakshmi R Bollu; Guang Gao; Fei Su; James Briggs; Xiaojing Liu; Tamar Melman; John M Asara; Isaiah J Fidler; Lewis C Cantley; Jason W Locasale; Zhang Weihua
Journal:  Cancer Res       Date:  2014-12-15       Impact factor: 12.701

10.  Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine.

Authors:  R Kinscherf; V Hack; T Fischbach; B Friedmann; C Weiss; L Edler; P Bärtsch; W Dröge
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.